Business
Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2025 and Business Highlights
Expect to report topline results for ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer’s disease, in late 2026Lead clinical candidate IND filing in Acumen’s Enhanced Brain Delivery (EBDTM) program targeted for mid-2027, following strong preclinical data and $35.75 million private placement to advance candidates in AβO-selective EBD portfolioCash, cash equivalents and marketable securities of $116.9 million as of Dec. 31, 2025, expected to suppor
About this update from Acumen Pharmaceuticals, Inc.
[{"type":"image","alt":"Acumen Pharmaceuticals, Inc.","displaySize":"","headline":null,"caption":"Acumen Pharmaceuticals, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":62,"url":"https://media.zenfs.com/en/globenewswire.com/cbb5dd6e9a075046255d7d2e82373879"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/7T0IxEJj0Y5HSLwhPACVvg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTg3/https://media.zenfs.com/en/globenewswire.com/cbb5dd6e9a075046255d7d2e82373879","width":300,"height":62}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Expect to report topline results for ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer’s disease, in late 2026","length":161,"tagName":"p"}]},{"val":[{"type":"text","content":"Lead clinical candidate IND filing in Acumen’s Enhanced Brain Delivery (EBDTM) program targeted for mid-2027, following strong preclinical data and $35.75 million private placement to advance candidates in AβO-selective EBD portfolio","length":233,"tagName":"p"}]},{"val":[{"type":"text","content":"Cash, cash equivalents and marketable securities of $116.9 million as of Dec. 31, 2025, expected to support current clinical and operational activities into early 2027","length":167,"tagName":"p"}]},{"val":[{"type":"text","content":"Company to host conference call and webcast today at 8:00 a.m. ET","length":65,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":626,"olType":false},{"type":"text","content":"NEWTON, Mass., March 26, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD), today reported financial results for the full year ended December 31, 2025 and provided a business update.","length":411,"tagName":"p"},{"type":"text","content":"“2025 was defined by significant clinical progress supporting our Phase 2 ALTITUDE-AD study investigating our lead therapeutic candidate, sabirnetug, and the expansion of our pipeline via a notable Enhanced Brain Delivery (EBDTM) partnership to develop a transferrin-receptor-targeting blood-brain barrier-penetrating therapy,” said Daniel O’Connell, Chief Executive Officer of Acumen. “2026...